150 related articles for article (PubMed ID: 8487567)
1. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
2. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
Cmolik BL; Spero JA; Magovern GJ; Clark RE
J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
[TBL] [Abstract][Full Text] [Related]
3. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin.
Muntean W; Zenz W; Edlinger G; Beitzke A
Thromb Haemost; 1997 Jun; 77(6):1223. PubMed ID: 9241765
[No Abstract] [Full Text] [Related]
4. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V.
Bänninger H; Hardegger T; Tobler A; Barth A; Schüpbach P; Reinhart W; Lämmle B; Furlan M
Br J Haematol; 1993 Nov; 85(3):528-32. PubMed ID: 8136275
[TBL] [Abstract][Full Text] [Related]
5. [A case positive for the inhibitor for coagulation factor V].
Nakagoshi R; Takamiya O; Nakata S; Ishikawa S; Higuchi Y; Okumura N; Ogiso Y
Rinsho Byori; 1999 Oct; 47(10):971-5. PubMed ID: 10590673
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
[TBL] [Abstract][Full Text] [Related]
7. Acquired inhibitors of factor V.
Feinstein DI
Thromb Haemost; 1978 Jun; 39(3):663-74. PubMed ID: 705695
[TBL] [Abstract][Full Text] [Related]
8. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.
Zehnder JL; Leung LL
Blood; 1990 Nov; 76(10):2011-6. PubMed ID: 2242423
[TBL] [Abstract][Full Text] [Related]
9. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.
Adams JD; Jones S; Brost BC
J Reprod Med; 2001 Oct; 46(10):909-12. PubMed ID: 11725736
[TBL] [Abstract][Full Text] [Related]
10. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases.
Spero JA
J Neurosurg; 1993 May; 78(5):817-20. PubMed ID: 8468613
[TBL] [Abstract][Full Text] [Related]
11. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin.
Israels SJ; Israels ED
Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):249-54. PubMed ID: 8037345
[TBL] [Abstract][Full Text] [Related]
12. The effects of hepes buffer on clotting tests, assay of factors V and VIII and on the hydrolysis of esters by thrombin and thrombokinase.
Roberts PS; Hughes HN; Fleming PB
Thromb Haemost; 1976 Feb; 35(1):202-10. PubMed ID: 989187
[TBL] [Abstract][Full Text] [Related]
13. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.
Streiff MB; Ness PM
Transfusion; 2002 Jan; 42(1):18-26. PubMed ID: 11896308
[TBL] [Abstract][Full Text] [Related]
14. An acquired factor V inhibitor: clinical and laboratory features.
Shastri KA; Ho C; Logue G
J Med; 1999; 30(5-6):357-66. PubMed ID: 10851568
[TBL] [Abstract][Full Text] [Related]
15. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant.
Zumberg MS; Waples JM; Kao KJ; Lottenberg R
Am J Hematol; 2000 May; 64(1):59-63. PubMed ID: 10815789
[TBL] [Abstract][Full Text] [Related]
16. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent.
Carroll JF; Moskowitz KA; Edwards NM; Hickey TJ; Rose EA; Budzynski AZ
Thromb Haemost; 1996 Dec; 76(6):925-31. PubMed ID: 8972012
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child.
Muntean W; Zenz W; Finding K; Zobel G; Beitzke A
Acta Paediatr; 1994 Jan; 83(1):84-7. PubMed ID: 8193480
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin.
Arocas V; Lemaire C; Bouton MC; Bezeaud A; Bon C; Guillin MC; Jandrot-Perrus M
Thromb Haemost; 1998 Jun; 79(6):1157-61. PubMed ID: 9657441
[TBL] [Abstract][Full Text] [Related]
19. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery.
Flaherty MJ; Henderson R; Wener MH
Ann Intern Med; 1989 Oct; 111(8):631-4. PubMed ID: 2802417
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
